Krystal Biotech, Inc.
KRYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.8% | 8.9% | -3.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.2% | 92.5% | 94.3% | 94.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 42.3% | 40.9% | 41% | 45.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 81.2% | 39.9% | 40.5% | 49.9% |
| EPS | 2.741 | 1.33 | 1.24 | 1.58 |
| % Growth | 106.1% | 7.3% | -21.5% | – |
| EPS Diluted | 2.66 | 1.29 | 1.2 | 1.52 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 50.7% | 42.5% | 42.9% | 47.1% |